How large is the metformin market, and what is its growth trajectory?
The metformin market size has grown strongly in recent years. It will grow from $4.17 billion in 2024 to $4.48 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to rise in the prevalence of diabetes, growth in awareness of diabetes, and increasing healthcare spending.
The metformin market size is expected to see strong growth in the next few years. It will grow to $5.88 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to expansion in emerging markets, growing awareness, and adoption of metformin, aging Population, patent expiry and generic competition, increasing demand for combination therapies, increased awareness of side effects, and safety concerns. Major trends in the forecast period include the launch of new products, lifestyle interventions, research and development, increasing partnerships, and advancements in manufacturing technology .
Get Your Free Sample of The Global Metformin Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16475&type=smp
What key drivers have fueled the metformin market’s development over the years?
The increasing prevalence of diabetes is expected to propel the growth of the metformin market going forward. Diabetes is a health issue that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it makes. The prevalence of diabetes is due to several factors, such as the obesity pandemic, genetic predispositions, lifestyle modifications, restricted access to healthcare, and exposure to particular toxins. Metformin assists in managing type 2 diabetes by lowering blood sugar, increasing weight loss, enhancing insulin sensitivity, and possibly providing other cardiovascular advantages. For instance, in February 2023, according to Diabetes Canada, a Canada-based non-profit organization, In Canada, the estimated prevalence of diabetes is projected to increase from 2,409,000 cases (15% of the population) in 2023 to 3,009,000 cases (17% of the population) by 2033. Therefore, the increasing prevalence of diabetes is driving the growth of the metformin market.
What is the segmentation for the metformin market?
The metformin market covered in this report is segmented –
1) By Product Type: Standard-Release Tablets, Slow-Release Tablets
2) By Dosage Type: 500MG, 750MG, 850MG, 1G
3) By End-user: Clinics, Hospitals, Homecare, Other End-Users
Subsegments:
1) By Standard-Release Tablets: 500 Mg, 850 Mg, 1000 Mg
2) By Slow-Release Tablets: 500 Mg, 750 Mg, 1000 Mg
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/metformin-global-market-report
Who are the most influential companies in the metformin market?
Major companies operating in the metformin market are Wockhardt Limited, Aarti Drugs, Abhilash Chemicals Private Limited, Farmhispania, Rochem International Inc., Jai Radhe Sales, Chr. Olesen Group, Aspire Lifesciences Pvt. Ltd., Ria Lifesciences Pvt. Ltd., Shree Sadguru, LGM Pharma, HRV Global Life Sciences, Octavius Pharma Pvt. Ltd., USV Private Limited, Zeon Pharma Industries India Pvt. Ltd., Atman Pharmaceuticals, Aastrid International Pvt. Ltd., Abhilasha Pharma, Anwita Drugs & Chemicals Pvt. Ltd., IOL Chemicals and Pharmaceuticals, Gangwal Healthcare, Granules India Limited, Alekhya Drugs Pvt. Ltd, Angels Pharma India Private Limited, Auro Laboratories Ltd.
What are the top industry trends projected to impact the metformin market?
Major companies operating in the metformin market are focusing on developing innovative diabetes medications, such as triple-drug FDC, to strengthen their position in the market. A triple-drug Fixed-Dose Combination (FDC) for diabetes medications typically refers to a single tablet or capsule combining three different antidiabetic medications. These combinations are designed to provide synergistic effects in managing blood sugar levels and improving overall glycemic control in patients with type 2 diabetes. For instance, in October 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical company, launched the first triple-drug fixed-dose combination (FDC) of teneligliptin with dapagliflozin and metformin in India. This FDC, branded as Zita DM, contains teneligliptin (20 mg), dapagliflozin (10 mg), and metformin SR (500 mg/1000 mg) in a fixed dose. It is designed to improve glycemic control in adult patients with Type 2 diabetes, particularly those whose diabetes is uncontrolled by metformin or who require the addition of teneligliptin and dapagliflozin as separate drugs.
What are the major regional insights for the metformin market, and which region holds the top position?
North America was the largest region in the metformin market in 2024. The regions covered in the metformin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Metformin Market Report 2025 Offer?
The metformin market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Metformin is an oral medication primarily used to treat type 2 diabetes, belonging to the biguanides class. It works by decreasing glucose production in the liver, increasing insulin sensitivity to improve glucose uptake by muscles, and reducing glucose absorption from the intestines.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16475
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
